INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Oct. 01, 2015 |
Jul. 28, 2016 |
Jan. 26, 2016 |
Jun. 30, 2015 |
Jun. 30, 2018 |
Jun. 30, 2017 |
Jun. 30, 2018 |
Jun. 30, 2017 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
| Termination of licensing agreement | $ 132,804 | |||||||||
| Agreement description | On March 31, 2016, the parties agreed to terminate the above described acquisition and to cancel any and all obligations assumed under the agreement. | |||||||||
| Intellectual property fees | $ 55,648 | |||||||||
| Description for right to purchase perpetual rights |
North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life. |
|||||||||
| Amortization expenses | $ 0 | $ 6,936 | $ 1,963 | $ 13,797 | $ 27,767 | $ 25,918 | ||||
| Common shares outstanding | 247,186,285 | 247,186,285 | 244,086,285 | 181,804,501 | ||||||
| Therakine, Ltd. [Member] | ||||||||||
| License cost | $ 2,750,000 | |||||||||
| Aggregate purchase price | $ 250,000 | $ 250,000 | $ 250,000 | $ 250,000 | ||||||
| Escrow deposit | $ 75,000 | 75,000 | ||||||||
| Therakine, Ltd. [Member] | Minimum [Member] | ||||||||||
| Milestone payments and royalties | 5.00% | |||||||||
| Therakine, Ltd. [Member] | Maximum [Member] | ||||||||||
| Milestone payments and royalties | 12.00% | |||||||||
| Naltrexone Implant Formulation [Member] | ||||||||||
| Estimated useful life | 10 years | |||||||||
| Aggregate purchase price | $ 1,132,000 | $ 1,132,000 | ||||||||
| Purchase obligation to pay | $ 1,000,000 | |||||||||
| Acquired rights, title and interest payment period | 14 months | |||||||||
| Common shares outstanding | 3,000,000 | |||||||||
| Market value | $ 0.044 | |||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The par value of the auction market preferred security. No definition available.
|
| X | ||||||||||
- Definition Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The loss recognized on termination of a contract. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. No definition available.
|
| X | ||||||||||
- Definition The amount purchased during the period under an unrecorded unconditional purchase obligation (for example, under the take-or-pay or throughput contract). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|